Literature DB >> 16681060

The efficacy of unoprostone isopropyl as an adjunct to topical beta-blocker in patients with open angle glaucoma: a-6-month study.

Yupin Leelachaikul1, Ataya Euswas.   

Abstract

OBJECTIVES: To assess the efficacy and safety of unoprostone isopropyl as an adjunctive treatment to topical beta-blocker in patients with primary open angle glaucoma (POAG). STUDY
DESIGN: This was a prospective, open-label clinical study. MATERIAL AND
METHOD: A total of 44 eyes of 22 eligible patients whose intraocular pressure (IOP) was inadequately controlled by topical beta-blocker were enrolled. Inclusion criteria consisted of patients with primary open angle glaucoma who either had IOP measurements > or = 22 mmHg while on topical beta-blocker monotherapy or had IOP measurements > or = 18 mmHg while on dual therapy (topical beta-blocker and a second drug of a different class which was to be discontinued prior to the study to allow washing out of its effects). INTERVENTION: Baseline IOP, pupil size, blood pressure and pulse rate were initially measured; the patients were then examined at 2nd, 4th, 8th, 12th, 18th and 24th weeks of following commencement of topical unoprostone isopropyl therapy (given twice daily). MAIN OUTCOME MEASURES: IOP pupil size, blood pressure and pulse rate were measured and were compared to baseline values.
RESULTS: In 44 eyes of 22 eligible patients, unoprostone isopropyl resulted in a statistically significant IOP reduction of 24.6% (p < 0.02). The mean systolic blood pressure decreased from 132.79 +/- 22.11 mmHg (range 100-180 mmHg) at baseline to 125.77 +/- 18.40 mmHg (range 80-160 mmHg) at 24th week after unoprostone isopropyl administration. This reduction was statistically significant (p = 0.002) but was unlikely to have clinical importance. Both mean diastolic blood pressure (p = 0.344), pulse rate (p = 0.306), and pupil diameter (p = 0.107) were not significantly affected.
CONCLUSION: Topical unoprostone isopropyl beneficially provides additive IOP lowering effect to topical beta-blocker in patients with primary open angle glaucoma. No serious systemic side effects were found in the present study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16681060

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.